20 articles
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
Researchers discovered why fibrolamellar carcinoma resists immunotherapy and found an existing drug can free trapped T cells to fight it.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
Breakthrough antibodies completely prevent EBV infection in lab models, offering hope against virus linked to cancer and chronic disease.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months — reshaping treatment strategy.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
New biotech innovations are advancing prostate cancer therapy with promising approaches for better patient outcomes.
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
Scientists discover why identical cancer treatments work for some patients but fail for others, revealing hidden drug reservoirs in cells.
USC researchers unlocked a scalable supply of engineered immune-cell precursors that fight tumors and may revolutionize cancer immunotherapy.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
